J. Goldman & CO LP Trevi Therapeutics, Inc. Transaction History
J. Goldman & CO LP
- $3.53 Billion
- Q4 2024
A detailed history of J. Goldman & CO LP transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 537,609 shares of TRVI stock, worth $2.22 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
537,609
Previous 148,917
261.01%
Holding current value
$2.22 Million
Previous $497,000
360.76%
% of portfolio
0.06%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding TRVI
# of Institutions
113Shares Held
77.6MCall Options Held
218KPut Options Held
182K-
Nea Management Company, LLC Timonium, MD11.4MShares$47 Million3.46% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.7MShares$44 Million2.72% of portfolio
-
Viking Global Investors LP4.4MShares$18.2 Million0.06% of portfolio
-
Rubric Capital Management LP New York, NY4.21MShares$17.4 Million0.3% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.15MShares$17.1 Million0.04% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $241M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...